Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
輝瑞ELREXFIO在2期MagnetisMM-3研究中顯示的中位總生存期超過2年。
- Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months
- MagnetisMM-3患者的中位總生存期（OS）爲24.6個月，中位無進展生存期（PFS）爲17.2個月。
Pfizer Inc. (NYSE:PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
輝瑞公司（NYSE：紐交所）今天宣佈了重度預處理復發或難治性多發性骨髓瘤（RRMM）患者elranatamab-bcmm相位2 MagnetisMM-3研究的詳細總生存期（OS）結果。該研究表明，樞軸單臂試驗的A隊列（n = 123）的中位OS爲24.6（95％CI，13.4，NE）個月。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。